PATOU GARY sold $70K of XENE
PATOU GARY sold 1,322 shares of Xenon Pharmaceuticals Inc. (XENE) at $53.14 on 2026-06-05 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
A director’s open-market sale under a pre-arranged 10b5-1 plan is generally treated as routine compliance rather than a fundamental change, but it can marginally influence sentiment.
Market read
Insider selling disclosure for XENE; likely low incremental trading signal absent other catalysts.
What to watch
The filing does not indicate size relative to total float or whether other insiders/funds are simultaneously trading; without that context, signal is weak.
Background
The article is an SEC EDGAR Form 4 insider transaction disclosure for Xenon Pharmaceuticals (XENE).
Ticker impact
Xenon Pharmaceuticals director Patou Gary filed an SEC Form 4 selling 1,322 shares in an open-market transaction under a 10b5-1 plan.
Likely limited impact; any effect should be small and short-lived unless accompanied by other news.
The disclosure is a Form 4 insider sale (not a buy), with a modest dollar value (~$70k) and explicitly pre-arranged 10b5-1 structure, which usually reduces interpretive weight.
Market effects
No clear sector read-through from a single, pre-arranged director sale.
None indicated.
None indicated.
Counterpoint
Even 10b5-1 sales can coincide with internal risk/valuation concerns; traders may still fade strength or tighten risk around XENE.
Key entities
- issuerXenon Pharmaceuticals Inc.
Company whose shares were sold by a director via an open-market transaction.
- insiderPatou Gary
Director who sold 1,322 shares on 2026-06-05 under a 10b5-1 plan.
